NCT06839053 - Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

July 1, 2032

Conditions

Chronic Lymphocytic LeukemiaMantle Cell LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Mantle Cell LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Mantle Cell LymphomaRefractory Small Lymphocytic LymphomaSmall Lymphocytic Lymphoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Gastrointestinal Endoscopy

Undergo endoscopy

BIOLOGICAL

Rituximab

Given IV

DRUG

Sonrotoclax

Given PO

DRUG

Zanubrutinib

Given orally (PO)

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle